Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Symcel AB. (6/27/18). "Press Release: New Board Members Bolstering Expansion into Diagnostics Market".

Organisations Organisation Symcel AB
  Organisation 2 Gyros AB
  Today Gyros Protein Technologies AB
  Group Gyros (Group)
Products Product calScreener™
  Product 2 clinical diagnostics
Persons Person Walldén, Erik (Gyros 200903–201310 CEO RESIGNED 10/13 before Affibody CEO + Biacore CEO + Pyrosequencing CEO)
  Person 2 Löfås, Stefan (Symcel AB 201806 Board Member before GE Heatlhcare Bio-Sciences + Biacore International)
     


Symcel – the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, the calScreener™ – has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås. Both will play a key role in bolstering the full execution of the company’s corporate strategy to grow business in the research market and develop much needed solutions for clinical diagnostics.

Erik Walldén, who is internationally recognized for his success in building prosperous life science companies and driving business in the medical technology sector, will play a pivotal role in the implementation of the company’s business, sales and marketing strategies and help it develop a larger international network of contacts and prospects.

Stefan’s strong scientific expertise, together with vast experience in the valuation and acquisition of companies, will be put to use in strategically assessing life science companies that Symcel should partner with. He will also utilise his solid network within cell analysis and pharmaceutical drug development for business development to aid the company in its growth drive. Moreover, Stefan will in part focus on Symcel’s unique technological offering – putting his extensive scientific and industrial R&D experience to effective use.

During 30 years of international life science industry management, Erik has been responsible for the global launch of a number of technologies, establishing and restructuring companies, implementation of targeted issues and stock market listings. Previously, Erik was the CEO of Gyros, Affibody Holding, Biacore International and Pyrosequencing and has held senior positions at PerSeptive Biosystems, Pharmacia Biosensor and Pharmacia Biotech. Moreover, Walldén is presently Chairman of the Board at Cavidi and Lumicks, and holds board level positions at Virgin Instruments, Beactica and CellSeed.

Stefan Löfås was the Chief Scientific Officer at Biacore International and until recently the Scientific Director at GE Healthcare Bio-Sciences with strategic responsibility for technology development.

We are delighted that both Erik Walldén, and Stefan Löfås are joining the board. Their appointments will play a crucial role in the realization of the ambitious corporate strategy that we set ourselves – enabling Symcel to increase the flow of business from the R&D sector and expand into the clinical diagnostics space”, commented Jesper Ericsson, CEO of Symcel.


About Symcel

Symcel provides a novel cell-based assay tool for real-time cellular bioactivity measurements. Our solution is a fast label-free phenotypic screening technology for direct measurements of cell metabolism that provides powerful answers to whether cells are dead or alive. Symcel is a privately held biotechnology company located in Stockholm Sweden. Symcel was founded in 2004 by Dr. Dan Hallén and Prof. Ingemar Wadsö (Kemicentrum, Lund University). Dr Wadsö is a leading authority around bioactivity measurements and has together with colleagues at Lund University been instrumental in the development of the field. The current research team at Symcel has extensive experience in multiple disciplines within the biotechnology industry as well as the pharmaceutical development industry.

See more about our board members in the About Us page and start following Symcel on LinkedIn for our latest news.

   
Record changed: 2018-08-04

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Symcel AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top